Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)